Skip to content
Screener

CRISPR Therapeutics CRSP Q3 2025 earnings

Reported November 10, 2025 · Before market open

Revenue$889.0KMiss by $8.2M
EPS-$1.17Beat by $0.09
Revenue estimate$9.1M
EPS estimate-$1.26

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$14.8M
EPS estimate-$1.06

Financials

Q3 2025

Income statement

See full
Revenue$889.0K+47.7%
Operating income-$132.1M-19.9%
Net income-$106.4M-23.9%
EPS (diluted)-$1.17-15.8%

Balance sheet

See full
Cash & equivalents$286.5M+27.0%
Total debt$211.0M-7.3%
Total equity$1.9B-1.2%
Total assets$2.2B-0.5%

Cash flow

See full
Operating cash flow-$84.6M+20.8%
CapEx$74.0K-66.2%
Free cash flow-$84.7M+20.9%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$5.89B+47.3%
Enterprise value$5.82B+45.4%
P/S153.8×+134×

Profitability

See full
Operating margin-1,498.3%—
Net margin-1,273.7%—
FCF margin-790.7%-915pp

Returns & leverage

See full
Return on equity-25.3%—
Debt / equity0.1×0.0×
Current ratio16.2×-5.4×

Segments

By product

See full
Grant$889.0K+47.7%
Collaboration Revenue-—

FAQ

When did CRISPR Therapeutics report Q3 2025 earnings?
CRISPR Therapeutics (CRSP) reported Q3 2025 earnings on November 10, 2025 before market open.
What were CRISPR Therapeutics's Q3 2025 revenue and EPS?
CRISPR Therapeutics reported revenue of $889.0K and eps of $-1.17 for Q3 2025.
Did CRISPR Therapeutics beat estimates in Q3 2025?
Revenue missed the consensus estimate of $9.1M by $8.2M. EPS beat the consensus estimate of $-1.26 by $0.09.
How did CRISPR Therapeutics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 47.7% from $602.0K a year earlier and eps declined 15.8% from $-1.01.
Where can I find CRISPR Therapeutics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-273329) and the 10-Q periodic report (0001193125-25-273337) directly on SEC EDGAR. The filing index links above go to sec.gov.